secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zenas BioPharma, Inc. (ZBIO)
CIK:        0001953926
Form:       8-K
Filed at:   2026-05-13T10:14:34+00:00
Accession:  0001104659-26-059700
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zenas BioPharma Q1 net loss $81M; obexelimab BLA on track
---------------------------------------------------------

- Net loss $81.0M in Q1 2026 vs $33.6M in Q1 2025; R&D expenses rose to $60.4M.
- Cash and investments $718.5M as of Mar 31; raised $419M year-to-date from offerings and debt facility.
- Obexelimab BLA for IgG4-RD expected this quarter; EMA filing H2 2026; INDIGO data at EULAR June 4.
- Phase 2 SunStone SLE trial enrollment completed; topline results expected Q4 2026.
- Director Tomas Kiselak did not stand for re-election; board size reduced by one.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1953926/000110465926059700/0001104659-26-059700-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1953926/000110465926059700/tm2614295d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-059700

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer